Author

Elena Fernández

Observed name: Elena Fernandez

Institution: Molecular Partners (Switzerland)

Observed institution: Molecular Partners (Switzerland)

ORCID: 0000-0002-1835-0573

Observed ORCID: 0000-0002-1835-0573

OpenAlex ID: A5101991260

Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study

2026 · Neeltje Steeghs, Carlos Gomez-Roca, et al. · Nature Cancer · 10

Effect of MP0317, a FAP x CD40 DARPin, on safety profile and tumor-localized CD40 activation in a phase 1 study in patients with advanced solid tumors.

2024 · Neeltje Steeghs, Carlos A. Gomez-Roca, et al. · Journal of Clinical Oncology · 8

Phase I study of MP0317, a FAP-dependent DARPin, for tumor-localized CD40 activation in patients with advanced solid tumors.

2023 · Carlos A. Gomez-Roca, Neeltje Steeghs, et al. · Journal of Clinical Oncology · 5

1475 A phase 1 study to characterize the safety and tolerability of MP0317, a tumor targeting FAP dependent CD40 agonist DARPin, in patients with relapsed/refractory solid tumors

2022 · Hilde De Winter, Elena Fernandez, et al. · Journal for ImmunoTherapy of Cancer · 1

Table S1 from Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx

2023 · Tristan M. Sissung, Ariel M. Ley, et al.

Figure S1 from Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx

2023 · Tristan M. Sissung, Ariel M. Ley, et al.

Figure S1 from Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx

2023 · Tristan M. Sissung, Ariel M. Ley, et al.

Works count: 7

Citation count: 24

H-index: 3

I10-index: 1